837 results on '"Andreesen R"'
Search Results
52. Interleukin-10 Promotes NK Cell Killing of Autologous Macrophages by Stimulating Expression of NKG2D Ligands
53. Erratum to: Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose Treosulfan
54. Recipient NOD2/CARD15 status affects cellular infiltrates in human intestinal graft-versus-host disease
55. Synergistic action of TLR5 and NOD2/CARD15: Identification of a new risk factor of GvHD and treatment related mortality: V888
56. Purity and stability of human regulatory T cells upon in vitro expansion: comparison of MACS- and FACS-based isolation strategies based on CD45RA, CD127 and CD49d expression: V887
57. Phase I trial of adoptive immunotherapy of cancer patients using monocyte-derived macrophages activated with interferon γ and lipopolysaccharide
58. The human lysozyme gene undergoes stepwise demethylation during phagocyte maturation
59. The role of genetic variants of NOD2/CARD15, a receptor of the innate immune system, in GvHD and complications following related and unrelated donor haematopoietic stem cell transplantation
60. Expression of CD68 in Non-Myeloid Cell Types
61. Loss of FOXP3 expression after in vitro expansion of human CD4+CD25+CD127− regulatory T-cells
62. Genetic variations in the NOD2/CARD15 gene are associated with bacteraemia and sepsis after allogeneic stem cell transplantation
63. Prospective evaluation of the NIH staging criteria in chronic GvHD - results of an interim analysis of the German Multicentre Validation Trial
64. Stage of GvHD and NOD2/CARD15 genotype affect cellular infiltrates in intestinal GvHD
65. Targeting tumor-associated ‘wound healing’ mechanisms: V3
66. Differentiation of Human Tumour-associated Dendritic Cells into Endothelial-like Cells: An Alternative Pathway of Tumour Angiogenesis
67. Variations in 1α,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 serum levels during allogeneic bone marrow transplantation
68. In vitro monitoring of endothelial complications following hematopoietic allogeneic stem cell transplantation
69. In vitro monitoring of defibrotide prophylaxis for endothelial complications in allogeneic stem cell transplantation
70. Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomib
71. Chemomodulation of drugs involved in multidrug resistance in chronic lymphatic leukemia of the B-cell type
72. Pneumologische Probleme nach allogener Stammzelltransplantation
73. Interferon (IFN)-γ is a main mediator of keratinocyte (HaCaT) apoptosis and contributes to autocrine IFN-γ and tumour necrosis factor-α production
74. Oligotide, a defibrotide derivative, protects the endothelium from non-myeloablative conditioning toxicity in vitro
75. Anti-inflammatory and angiostatic therapy in chemorefractory multisystem Langerhansʼ cell histiocytosis of adults
76. Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia
77. Developmental regulation of granulocyte-macrophage colony-stimulating factor production during human monocyte-to-macrophage maturation
78. Combined Anti-Inflammatory and Angiostatic Treatment of Hormone Refractory Prostate Cancer: O418
79. NOD2/CARD15 Mutations and Outcome Following Allogeneic SCT: Strong Impact in Patients Requiring Treatment of GvHD: O289
80. Pioglitazone and Rofecoxib Combined with Angiostatic Scheduling of Capecitabine in Advanced Cholangiocarcinoma: O236
81. Adoptive T Cell Therapy Using Antigen-Specific CD8+ T Cells for the Treatment of Patients with Metastatic Melanoma: A Phase I Clinical Study: O120
82. Expression of PD-L1 on Human Tumors Inhibits Tumor-Specific T Cell Responses: O73
83. Regression of nonresectable inflammatory myofibroblastic tumours after treatment with nonsteroidal anti-inflammatory drugs
84. NOD2/CARD15 mutations of recipients and donors associate with GvHD and TRM following allogeneic stem cell transplantation - results in 2 independent cohorts of patients
85. Long-Term Results of First-Line Sequential High-Dose Etoposide, Ifosfamide, and Cisplatin Chemotherapy Plus Autologous Stem Cell Support for Patients With Advanced Metastatic Germ Cell Cancer: An Extended Phase I/II Study of the German Testicular Cancer Study Group
86. High frequency of functionally active Melan-A specific T cells in a patient with progressive melanoma: Implications for immunotherapy: P1036
87. PD-L1 on murine and human tumors and its possible role in immune evasion: P997
88. Pioglitazone and rofecoxib combined with angiostatic scheduling of chemotherapy in advanced renal cell carcinoma: P973
89. Regression of non-resectable inflammatory myofibroblastic tumors after treatment with non-steroidal anti-inflammatory drugs: P959
90. Pioglitazone and rofecoxib combined with angiostatic scheduling of chemotherapy in advanced biliary tract cancer and hepatocellular carcinoma: P777
91. Hematopoietic progenitor cells increase after acute cerebral ischemic insult: P741
92. The number of IFN-gamma secreting anti host reactive T cells correlates with GvH disease after allogeneic transplantation: P477
93. Pioglitazone and rofecoxib combined with angiostatic scheduling of chemotherapy in secondline therapy of advanced melanomas and pre-treated soft tissue sarcomas: V382
94. Apoptosis of antigen-specific T cells in melanoma patients: Analysis of in vitro generated Melan-A specific T cells following adoptive transfer: V381
95. In vitro monitoring of endothelial cell damage and activation by serum from patients after allogeneic stem cell transplantation: V372
96. Prognostic impact of genetic instability in CD34 positive hematopoietic progenitor cells from patients with acute myeloid leukemia in first complete remission: V221
97. Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial
98. Stem cell factor (SCF) increases the expression and function of very-late-antigen (VLA)-4 and VLA-5 on CD34+ hematopoietic progenitor cells: 803
99. Stimulation of human CD34+ hematopoietic stem cells (HSC) with early-acting cytokines results in an increased engraftment of myeloid progenitor cells in NOD/SCID mice: 802
100. Characterization of TLR2 promoter polymorphisms in sepsis patients: 706
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.